Key Highlights Shares of Tempus AI surged 15% on Thursday, pushing its five-session rally to approximately 40% CEO Eric Lefkofsky projects $100M in revenue from tissue scanning diagnostics an
Tempus AI (TEM) shares soared 15% Thursday following CEO Eric Lefkofsky’s presentation of Medicare reimbursement projections at the Morgan Stanley 24th Annual Global Healthcare Conference. The healthcare technology company’s stock has now rallied nearly 40% across the last five trading sessions, approaching its strongest close since November 2025.
During his presentation, Lefkofsky outlined expectations for $80 million to $100 million in reimbursements next year from the company’s solid tumor tissue scanning diagnostic. Additionally, he forecasted $250 million to $300 million in revenue potential from its liquid biopsy offering, pending regulatory approval anticipated in the latter half of 2027.
The revenue guidance provided investors with the confidence needed to return to the stock following a challenging period after the company’s July acquisition news.
In July, Tempus announced plans to purchase cancer diagnostics firm Personalis for $1.5 billion, or $16.25 per share, primarily through stock compensation. The market’s initial reaction to the stock-heavy deal structure was negative, driving TEM shares lower. However, since bottoming at $41.55 on July 29, the stock has staged a remarkable 92% comeback.
In addition to its diagnostic offerings, Lefkofsky emphasized the data licensing division as a critical growth catalyst. This segment expanded 36% in the most recent quarter and features multi-year agreements valued above $100 million each with leading pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, GSK, Merck and BioNTech.
According to Lefkofsky, Tempus maintains a database encompassing 50 million patients alongside established partnerships with hospitals and pharmaceutical firms that provide a competitive advantage in the data licensing arena.
The pending Personalis transaction is anticipated to bolster Tempus’ molecular residual disease capabilities while driving test pricing beyond $1,000 per test in the future.
For the second quarter ending July 30, Tempus disclosed revenue of $382.5 million. The diagnostics division accounted for 76% of total sales. The company also highlighted $200 million in fresh licensing contracts within its data and applications division.
Notwithstanding the recent surge, the Street’s consensus target price stands at $66.56, now indicating approximately 17% downside from current trading levels. TEM maintains a Moderate Buy rating supported by 10 Buy recommendations and 7 Hold ratings issued in the past three months.
Addressing concerns about the stock’s rapid ascent, Lefkofsky dismissed suggestions of overvaluation. He emphasized the company’s commitment to achieving 25% annual growth throughout the next decade rather than fixating on near-term volatility. “If you got to bet at all, every day of the week and twice on Sunday, we over-deliver,” he stated.
ARK Innovation ETF (ARKK), which maintains TEM as its third-largest holding after Tesla and SpaceX, advanced 4.3% on Thursday. ARK Invest had accumulated approximately 85,000 TEM shares in March while reducing its Meta allocation.
Over the past month, TEM has climbed more than 60%. The stock’s current five-day winning streak represents its most robust performance since the July trough.
The post Tempus AI (TEM) Stock Surges 92% Since July as CEO Reveals Medicare Revenue Projections appeared first on Blockonomi.
